Navigation Links
Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
Date:5/14/2009

nflammatory diseases, including ulcerative colitis in an ongoing companion Phase 2 study."

About MDX-1100 in Rheumatoid Arthritis

MDX-1100 is a fully human antibody that targets IP-10 (also known as CXCL-10), a chemokine expressed in association with multiple inflammatory disease indications. The MDX-1100 Phase 2 study in RA enrolled 70 patients with active disease while on methotrexate. Patients in the study were randomized to receive either placebo or MDX-1100 (10 mg/kg) every two weeks for a total of six doses. The primary endpoint of the study was ACR20 response at 12 weeks. Secondary endpoints included other clinical response assessments, pharmacokinetics of MDX-1100, and potential biomarkers of activity.

According to the American College of Rheumatology, 1.3 million adult Americans have been diagnosed with rheumatoid arthritis, a chronic autoimmune disease that develops when certain cells of the immune system inappropriately attack healthy joint tissue, thereby causing swelling, inflammation and damage of joints, as well as systemic inflammation and damage of other tissues.

About MDX-1100 in Other Indications

MDX-1100 is also being explored as a treatment for ulcerative colitis (UC). A Phase 2 randomized, double-blind, placebo-controlled study in patients with active UC while continuing standard UC therapy is ongoing. The Phase 2 trial is expected to enroll up to 106 patients at multiple centers internationally. Patients in the study are randomized to receive either placebo or MDX-1100 (10 mg/kg) every two weeks for a total of four doses. The primary endpoint of the study is response rate at 8 weeks. Clinical response is based on the Mayo score, a composite endpoint that assesses stool frequency and the amount of bloody stool per day as recorded in a patient diary, physician global assessment and the assessment of colon mucosal inflammation ascertained by endoscopy.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
7. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
8. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
9. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
10. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
11. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014  Decision Resources Group finds that the market for ... billion by 2023 in the United States ... , Italy , Spain ... Japan . The biosimilar erosion of Roche/Genentech/Chugai,s Avastin ... by the launch of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s Lonsurf, ...
(Date:8/28/2014)... , Aug. 28, 2014 Levi & ... commenced in the United States District Court for the ... of investors who purchased Galectin Therapeutics Inc. ("Galectin" or ... and July 28, 2014. For more information, ... alleges that during the Class Period the Company violated ...
(Date:8/28/2014)... , Aug. 28, 2014 Nonin Medical, ... leader in noninvasive medical monitoring, today announced that the ... Model 3231 OEM/eHealth finger pulse oximeter for use in ... pulse oximeter plugs into a telemedicine hub or kiosk ... pulse rate in pediatric to adult patients. The Model ...
Breaking Medicine Technology:The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2
... to Produce Therapeutic Proteins at Tumor,Site, ARLINGTON ... surgeons have delivered cancer fighting proteins through,skin flaps ... 79 percent reduction,in tumor volume, according to a ... Surgery(R), the official medical journal of the American,Society ...
... today announced the submission of a supplemental New ... Administration (FDA) for SEROQUEL XR(TM),(quetiapine fumarate) Extended-Release Tablets ... disorder (GAD), including maintenance of,antianxiety effect. It is ... an,atypical antipsychotic medicine in GAD. The submission is ...
Cached Medicine Technology:Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 2Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 8
(Date:8/28/2014)... 2014 Valero Renewable Fuels Company, LLC, ... VLO), and the Ports of Indiana hosted Lt. Gov. ... at a Port Appreciation and Welcome Celebration commemorating the ... , “The opening of Valero’s ethanol facility at the ... development win for the State of Indiana,” Ellspermann said. ...
(Date:8/28/2014)... HealthDay Reporter THURSDAY, Aug. ... electrical currents through the scalp to a specific network of ... day. In a small study of healthy young adults, ... networks involved in memory. That, in turn, boosted participants, performance ... the brain stimulation. During TMS, an electromagnetic coil is ...
(Date:8/28/2014)... IL (PRWEB) August 28, 2014 Data ... Supplement shows that while most hospitals utilize a basic ... health care information technology is still a challenge. ... the August issue of Health Affairs , and ... Forum’s Health Care Data Center, as well as Chantal ...
(Date:8/28/2014)... is hurting reproduction of the endangered Devils Hole pupfish, threatening ... few as 35 individuals, new research by the University of ... that geothermal water on a small shelf near the surface ... pupfish live is heating up as a result of climate ... , The hotter water, which now reaches more than ...
(Date:8/28/2014)... 28, 2014 Dr. Paul Kovatis is being ... the U.S. military for his efforts to treat many wounded ... Warriors Foundation and several other military organizations. Dr. Kovatis’ ... in WWII. Having five members of his immediate family ... Cemetery, it’s no wonder Dr. Kovatis is so dedicated to ...
Breaking Medicine News(10 mins):Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 2Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 3Health News:Electrical Pulses to Scalp May Boost Memory: Study 2Health News:Electrical Pulses to Scalp May Boost Memory: Study 3Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 2Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 3Health News:Climate change puts endangered Devils Hole pupfish at risk of extinction 2Health News:Climate change puts endangered Devils Hole pupfish at risk of extinction 3Health News:NJ Top Docs Presents, Dr. Paul Kovatis 2
... survey reveals that 61% of Australians are not aware of the ... the Salvation Army survey, binge drinking was "worryingly high" among teenage ... 41 % of the18 to 24-year-olds confessed to take not less ... ,"What is of such concern is that people don't know ...
... New York: An investigation into the degree of consequence type ... the condition before 50 years//, led to the finding that ... say Swedish researchers. ,The status of type ... measured with the presence of biological identification in the blood ...
... well known that the output of nerve cells is the ... is still unclear about how widely separated regions of the ... complex activity. A new study by neuroscientists at the University ... Francisco (UCSF) is getting to resolve this mystery. ...
... the degree of hangover one might experience, after a night ... delved into this arena, and studied the connection between the ... by being hangover less as compared to the ones with ... a hangover, characterized by an unbearable headache, nausea, dry mouth ...
... type 1 Diabetes was admitted to the Clinical Research Center ... // Four days later the North Shore suburban girl was ... body and ready to spend a few days at the ... to do well, her insulin was reduced day by day. ...
... would benefit a lot if they were given albumin ... in London and experts in Kenya have developed this ... with malaria. ,In initial studies less ... new treatment died, researchers said. "The observation is that ...
Cached Medicine News:Health News:The need for cancer warnings on alcohol packaging 2Health News:Slow brain waves integral in coordination of complex activity 2Health News:Molecular Medicine And Diabetes 2Health News:Molecular Medicine And Diabetes 3Health News:Molecular Medicine And Diabetes 4Health News:Molecular Medicine And Diabetes 5Health News:Molecular Medicine And Diabetes 6Health News:Molecular Medicine And Diabetes 7
The Biopro All Poly cup is a uniquely designed UHMWPE acetabular cup....
The Pe-Plus offers an additional clinical option for replacing the acetabulum....
BatCup cotyloid implant, designed for use in revision surgery, is an hemispherical metal cup, with grooves on the edges that house locking flanges, which are attached to the iliac bone by cancellous ...
The cementless acetabular shells form part of the Mallory head range of femoral and acetabular implants....
Medicine Products: